Caredx reports fourth quarter and full year 2022 results

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the fourth quarter and full year ended december 31, 2022. recent highlights achieved full year revenue of $321.8 million, an increase of 9% compared with full year 2021 revenue. highest ever q4 revenue of $82.
CDNA Ratings Summary
CDNA Quant Ranking